Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,252.20
Bid: 1,253.20
Ask: 1,253.60
Change: 0.00 (0.00%)
Spread: 0.40 (0.03%)
Open: 1,248.00
High: 1,255.60
Low: 1,221.60
Yest. Close: 1,243.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Lonza full-year results beat poll, confirms 2015 targets

ZURICH, Jan 24 (Reuters) - Swiss drugs industry supplier Lonza said on Thursday it expects to grow sales and profit further in 2013 helped by new technologies, as it posted better-than-expected full-year profit. The Basel-based firm, which makes pharmaceutical ingredients for drugmakers suc

24 Jan 13 06:15

INSIGHT-Evidence grows for narcolepsy link to GSK swine flu shot

By Kate Kelland, Health and Science Correspondent STOCKHOLM, Jan 22 (Reuters) - Emelie Olsson is plagued by hallucinations and nightmares. When she wakes up, she's often paralysed, unable to breathe properly or call for help. During the day she can barely stay awake, and often misses school

22 Jan 13 12:39

REFILE-INSIGHT-Evidence grows for narcolepsy link to GSK swine flu shot

By Kate Kelland, Health and Science Correspondent STOCKHOLM, Jan 22 (Reuters) - Emelie Olsson is plagued by hallucinations and nightmares. When she wakes up, she's often paralysed, unable to breathe properly or call for help. During the day she can barely stay awake, and often misses school

22 Jan 13 12:24

RPT-INSIGHT-U.S. government investment gives flu vaccines a shot in the arm

(Repeats story first published on Jan. 19) By Julie Steenhuysen CHICAGO, Jan 19 (Reuters) - Fighting the flu may soon get easier. As early as next year, more modern and more effective vaccines will hit the market, thanks to investments by the U.S. government and pharmaceutical c

22 Jan 13 11:59

INSIGHT-Evidence grows for narcolepsy link to GSK swine flu shot

By Kate Kelland, Health and Science Correspondent STOCKHOLM, Jan 22 (Reuters) - Emelie is plagued by hallucinations and nightmares. When she wakes up, she's often paralysed, unable to breathe properly or call for help. During the day she can barely stay awake, and often misses school or hav

22 Jan 13 06:55

RPT-INSIGHT-U.S. government investment gives flu vaccines a shot in the arm

19 Jan 13 15:47

RPT-INSIGHT-U.S. government investment gives flu vaccines a shot in the arm

(Repeats to additional subscribers, no changes to text) By Julie Steenhuysen CHICAGO, Jan 19 (Reuters) - Fighting the flu may soon get easier. As early as next year, more modern and more effective vaccines will hit the market, thanks to investments by the U.S. government and pha

19 Jan 13 15:45

INSIGHT-U.S. government investment gives flu vaccines a shot in the arm

By Julie Steenhuysen CHICAGO, Jan 19 (Reuters) - Fighting the flu may soon get easier. As early as next year, more modern and more effective vaccines will hit the market, thanks to investments by the U.S. government and pharmaceutical companies. And even bigger scientific advances are

19 Jan 13 13:00

HOW TO PLAY IT: Wading back into European equities

By David Randall NEW YORK, Jan 18(Reuters) - After more than three years of crisis, Europe's days as a no-man's land may be coming to an end. The Euro Stoxx 50, an index of blue chip European stocks, is up more than 30 percent as of Thursday from the low it hit on June 1. It gained a

18 Jan 13 18:42

UPDATE 1-Roche says US allows it to tap adult Tamiflu reserves

* Roche says extra Tamiflu supplies will have different packaging * Says spot shortages of children's liquid Tamiflu to continue * Safeway, Rite Aid ship additional vaccine to U.S. stores By Ransdell Pierson Jan 17 (Reuters) - Roche Holding AG said U.S. regulators will all

17 Jan 13 22:45

Wednesday broker round-up UPDATE

Anglo American: Goldman Sachs reduces target price from 1650p to 1500p and reiterates its sell recommendation. Antofagasta: Goldman Sachs ups target price from 1100p to 1120p and still recommends to sell. ARM Holdings: UBS increases target price from 750p to 900p, while downgrading to neutral. As

16 Jan 13 07:16

UPDATE 2-AstraZeneca's new CEO removes R&D, commercial heads

* Mackay and Zook to leave UK's second-biggest drugmaker * New structure removes management layer to speed decisions * Revamp comes ahead of results on Jan. 31, strategic review (Adds analyst comments, further details) By Ben Hirschler LONDON, Jan 15 (Reuters) - AstraZeneca's new chief executive s

15 Jan 13 15:43

UPDATE 1-AstraZeneca's new CEO removes R&D, commercial heads

(Adds further details on management changes, background) Jan 15 (Reuters) - AstraZeneca's new chief executive stamped his authority on the struggling drugmaker on Tuesday by removing the heads of research and commercial operations. Pascal Soriot, who took the helm at Britain's second-biggest pharmac

15 Jan 13 13:57

UPDATE 1-GSK files for U.S. approval of new diabetes drug

(Adds details on albiglutide, forecast sales and competitors) LONDON, Jan 14 (Reuters) - GlaxoSmithKline said on Monday it had filed for U.S. approval of its new once-weekly diabetes drug albiglutide and would make a similar submission shortly in Europe as it vies for a share of a crowded market. Al

14 Jan 13 11:19

GlaxoSmithKline submits new diabetes drug for US approval

Pharma giant GlaxoSmithKline (GSK) submitted its latest treatment for type two diabetes to the US Food and Drug Administration (FDA) for regulatory approval. The firm said albiglutide BLA, an investigational once-weekly treatment for adult patients, was not yet approved as a treatment for type two

14 Jan 13 10:38

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.